Product news

Share this article:
Cephalon has received FDA approval for Treanda (bendamustine hydrochloride), an injectable indicated for the treatment of patients with indolent B-cell non-Hodgkin's lymphoma.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters